Should Celecoxib Be Contraindicated in Patients Who Are Allergic to Sulfonamides?
- 577 Downloads
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, is a diaryl-substituted pyrazole derivative containing a sulfonamide substituent. Because of this structural component, celecoxib is contraindicated for use in patients who have demonstrated allergic reactions to sulfonamides. However, there is a lack of data demonstrating cross-reactivity among sulfonamide medications.
A sulfonamide is any compound with an SO2NH2 moiety. The major difference between sulfonamide antimicrobials and other sulfonamide-containing medications such as furosemide, thiazide diuretics and celecoxib, is that sulfonamide antimicrobials contain an aromatic amine group at the N4 position. This allows for division of the sulfonamides into 2 groups: aromatic amines (i.e., sulfonamide antimicrobials) and nonaromatic amines. In addition, sulfonamide antimicrobials contain a substituted ring at the N1-position; this group is not found with nonaromatic amine-containing sulfonamides.
Adverse reactions to sulfonamide antimicrobials include type I, or immunoglobulin (Ig) E-mediated reactions, hypersensitivity syndrome reactions, and severe skin reactions such as toxic epidermal necrolysis. The aromatic amine portion of the sulfonamide antimicrobial is considered to be critical in the development of latter 2 reactions. In susceptible individuals, the hydroxylamine metabolite is unable to be detoxified leading to a cascade of cytotoxic and immunological events that eventually results in the adverse reaction. Since celecoxib does not contain the aromatic amine, adverse reactions such as hypersensitivity syndrome reactions and toxic epidermal necrolysis would not be expected to occur at the same frequency as they do with sulfonamide antimicrobials. Similarly, for IgE-mediated reactions, the N1-substituent and not the sulphonamide moiety is important in determining specificity to antibodies. Celecoxib and other nonaromatic amine-containing sulfonamide medications do not contain the N1-substituent.
Cross-reactivity among the various sulfonamide-containing medications has also not been substantiated by published case reports. In fact, conflicting information exists in the literature. Reports showing lack of cross-reactivity balance the few case reports suggesting cross-reactivity.
Cross-reactivity between sulfonamide medications should be based on scientific data, including chemistry, metabolism, immune responses and clinical data. Based on the current information, there is no documentation for cross-reactivity between sulfonamide antimicrobials and other sulfonamide medications, such as celecoxib.
- 1.Welbanks L, editor. CPS: compendium of pharmaceuticals and specialties, 35th ed. Ottawa: Canadian Pharmacists Association, 2000: 289Google Scholar
- 2.Hardman J, Limbird L, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1057Google Scholar
- 6.Management of drug hypersensitivity: a practice parameter. Ann Allergy Asthma Immunol 1999; 83 (Pt 3): 665–700Google Scholar
- 12.Gould L, Reddy C, Zen B, et al. Life-threatening reaction to thiazides. NY State J Med 1980; 80: 1975–6Google Scholar
- 16.Cribb A, Spielberg S, Griffen G. N4-hydroxyation of sulfamethoxazole by cytochrome P450 of the CYP2C subfamily and microsomal reduction of its hydroxylamine metabolite in human and rat hepatic microsomes. Drug Metab Disp 1995; 23: 406–14Google Scholar
- 17.Cribb A, Miller M, Leeder J, et al. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Drug Metab Disp 1991; 19: 900–6Google Scholar
- 18.Spielberg S, Leeder J, Cribb A, et al. Is sulfamethoxazole hydroxylamine the proximal toxin for sulfamethoxazole toxicity? Eur J Clin Pharmacol 1989; 36Suppl.: A146Google Scholar
- 25.Shepherd G, Burton D. Administration of cephalosporin antibiotics to patients with a history to penicillin [abstract]. J Allergy Clin Immunol 1993; 91(1 Pt 2): 262Google Scholar
- 31.Bretza J. Thrombocytopenia due to sulfonamide cross-sensitivity. Wiscon Med J 1982; 81: 21–3Google Scholar
- 34.Conner C. Cross-sensitivity of sulfonamide antibacterials and antihypertensives. Drug Ther 1975; 5: 63–64Google Scholar
- 37.De Barrio M, Tornero P, Zubeldia J, et al. Fixed drug eruption induced by indapamide. Cross-reactivity with sulfonamides. Invest Allergol Clin Immunol 1998; 8: 253–5Google Scholar
- 40.Moseley V, Baroody N. Some observations on the use of acetazoleamide as an oral diuretic in various edmatous states and in uremia with hyperkaliemia. Am Pract Digest Treat 1955; 6: 558–66Google Scholar
- 42.Newman L, Lay C, O’Connor K, Russell M. Lack of cross-reactivity to sumatriptan in patients allergic to sulfonamides: a retrospective chart review [abstract]. Headache 1999; 39: 372Google Scholar
- 44.Data on file, Searle (Pharmacia), 2000Google Scholar
- 46.McMorran M, Morawiecka I. Celecoxib (Celebrex): one year later. Can Adv Drug React Newslett 2000; 10: 1–3Google Scholar
- 47.Physicians’ Desk Reference, 54th ed. Montvale (NJ): Medical Economics Company, 2000Google Scholar